Lihi Eder1, Jai Jayakar, Arane Thavaneswaran, Amir Haddad, Vinod Chandran, David Salonen, Cheryl F Rosen, Dafna D Gladman. 1. From the Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto; Western University, London; Division of Rheumatology, Department of Medicine, University of Toronto; Department of Medical Imaging, University of Toronto; Musculoskeletal Imaging, Mount Sinai Hospital; Department of Medical Imaging, University of Toronto; Division of Dermatology, Toronto Western Hospital and University Health Network Hospitals; Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto Psoriatic Arthritis Clinic, Toronto, Ontario, Canada.
Abstract
OBJECTIVE: To assess the usefulness of the MAdrid Sonographic Enthesitis Index (MASEI) in classifying patients as having psoriatic arthritis (PsA) and comparing entheseal abnormalities between patients with PsA, psoriasis alone (PsC), and healthy controls (HC). METHODS: Patients with PsC were assessed to exclude inflammatory arthritis. The MASEI scoring system was used to quantify the extent of ultrasonographic (US) entheseal abnormalities. The total MASEI score was categorized into items that reflected inflammatory abnormalities (MASEI-inflammatory) and chronic damage (MASEI-damage). Nonparametric tests were used to compare MASEI scores across the groups. A cutoff point of MASEI ≥ 20 was used to calculate the sensitivity and specificity of the MASEI to classify patients as having PsA. RESULTS: Patients with PsA (n = 50), PsC (n = 66), and HC (n = 60) were assessed. Total MASEI scores were higher in patients with PsA than in those with PsC, and both those groups were higher than HC (p < 0.0001). MASEI-inflammatory showed a similar trend (p < 0.0001). MASEI-damage was higher in patients with PsA compared to both patients with PsC and HC (p < 0.0001); however, no difference was observed between patients with PsC and HC. No significant difference in MASEI scores was found across the 3 groups in patients with a body mass index > 30. The sensitivity of the MASEI score to correctly classify patients as having PsA was 30% and the specificity was 95% when compared to HC and 89% when compared to PsC. CONCLUSION: The severity of US entheseal abnormalities is highest in patients with PsA followed by PsC and is lowest in healthy controls. MASEI can specifically classify patients as having PsA.
OBJECTIVE: To assess the usefulness of the MAdrid Sonographic Enthesitis Index (MASEI) in classifying patients as having psoriatic arthritis (PsA) and comparing entheseal abnormalities between patients with PsA, psoriasis alone (PsC), and healthy controls (HC). METHODS:Patients with PsC were assessed to exclude inflammatory arthritis. The MASEI scoring system was used to quantify the extent of ultrasonographic (US) entheseal abnormalities. The total MASEI score was categorized into items that reflected inflammatory abnormalities (MASEI-inflammatory) and chronic damage (MASEI-damage). Nonparametric tests were used to compare MASEI scores across the groups. A cutoff point of MASEI ≥ 20 was used to calculate the sensitivity and specificity of the MASEI to classify patients as having PsA. RESULTS:Patients with PsA (n = 50), PsC (n = 66), and HC (n = 60) were assessed. Total MASEI scores were higher in patients with PsA than in those with PsC, and both those groups were higher than HC (p < 0.0001). MASEI-inflammatory showed a similar trend (p < 0.0001). MASEI-damage was higher in patients with PsA compared to both patients with PsC and HC (p < 0.0001); however, no difference was observed between patients with PsC and HC. No significant difference in MASEI scores was found across the 3 groups in patients with a body mass index > 30. The sensitivity of the MASEI score to correctly classify patients as having PsA was 30% and the specificity was 95% when compared to HC and 89% when compared to PsC. CONCLUSION: The severity of US entheseal abnormalities is highest in patients with PsA followed by PsC and is lowest in healthy controls. MASEI can specifically classify patients as having PsA.
Authors: Brigitte Michelsen; Andreas P Diamantopoulos; Dag Magnar Soldal; Hilde Berner Hammer; Arthur Kavanaugh; Glenn Haugeberg Journal: RMD Open Date: 2017-08-16
Authors: Garifallia Sakellariou; Carlo Alberto Scirè; Antonella Adinolfi; Alberto Batticciotto; Alessandra Bortoluzzi; Andrea Delle Sedie; Orazio De Lucia; Christian Dejaco; Oscar Massimiliano Epis; Emilio Filippucci; Luca Idolazzi; Andrea Picchianti Diamanti; Alen Zabotti; Annamaria Iagnocco; Georgios Filippou Journal: Front Med (Lausanne) Date: 2020-05-07
Authors: Matthew T Patrick; Philip E Stuart; Kalpana Raja; Johann E Gudjonsson; Trilokraj Tejasvi; Jingjing Yang; Vinod Chandran; Sayantan Das; Kristina Callis-Duffin; Eva Ellinghaus; Charlotta Enerbäck; Tõnu Esko; Andre Franke; Hyun M Kang; Gerald G Krueger; Henry W Lim; Proton Rahman; Cheryl F Rosen; Stephan Weidinger; Michael Weichenthal; Xiaoquan Wen; John J Voorhees; Gonçalo R Abecasis; Dafna D Gladman; Rajan P Nair; James T Elder; Lam C Tsoi Journal: Nat Commun Date: 2018-10-09 Impact factor: 14.919